Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01897519 · ClinicalTrials.gov registry record · Phase 2
A Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk Surgery
A Phase 2 study, sponsored by AbbVie.
- Terminated
- Registry status
- Phase 2
- Development phase
- 56
- Enrollment target
NCT01897519 is a Phase 2 study that was terminated before completion, run by AbbVie. The registered enrollment target is 56 participants.
The verdict
NCT01897519, a Phase 2 study, was terminated before completion, sponsored by AbbVie.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 56 participants
- Enrollment target
Study Summary
This study will evaluate the safety and efficacy of ABT-719 in patients undergoing high risk major surgery.
Interventions
- DRUG Placebo
- DRUG ABT-719
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2013-05 |
| Est. Completion | 2014-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01897519
The ClinicalTrials.gov registry entry for NCT01897519 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01897519 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01897519 about?
NCT01897519 is a clinical study titled "A Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk Surgery". This study will evaluate the safety and efficacy of ABT-719 in patients undergoing high risk major surgery.
What is the current status of trial NCT01897519?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2013-05. Estimated completion is 2014-05.
What interventions are being tested in trial NCT01897519?
The interventions under investigation include: Placebo (DRUG), ABT-719 (DRUG).
Who is sponsoring clinical trial NCT01897519?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.